Managers / Q3 2024 · view latest →
Data Collective IV GP, LLC
CIK 0001664974 · 270 UNIVERSITY AVENUE, PALO ALTO, CA, 94301 · 650-521-7814
Summary
Data Collective IV GP, LLC reported $163M in U.S.-listed holdings across 6 positions for Q3 2024.
The portfolio is heavily concentrated: OKLO alone accounts for 34.3% of reported value.
The book was largely unchanged from Q2 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 82.6% · $135M
- Other · 17.4% · $29M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| EVLVEvolv Technologies Holdings, Inc. | HELD | +0 | 9.68M | +$15M | $39M |
| Rocket Lab USA, Inc. | HELD | +0 | 2.93M | +$14M | $29M |
| RXRXRecursion Pharmaceuticals, Inc. | HELD | +0 | 5.94M | −$5M | $39M |
| OKLOOklo Inc. | HELD | +0 | 6.92M | −$3M | $56M |
| Mind Medicine (MindMed) Inc. | HELD | +0 | 100.3K | −$152,532 | $570,991 |
| ROIVRoivant Sciences Ltd. | HELD | +0 | 3.9K | +$3,759 | $44,718 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | OKLOOklo Inc.history → | COM CL A | 34.25% | $56M | 6.92M |
| 2 | EVLVEvolv Technologies Holdings, Inc.history → | COM CL A | 23.99% | $39M | 9.68M |
| 3 | RXRXRecursion Pharmaceuticals, Inc.history → | CL A | 23.95% | $39M | 5.94M |
| 4 | Rocket Lab USA, Inc. | COM | 17.44% | $29M | 2.93M |
| 5 | Mind Medicine (MindMed) Inc. | COM NEW | 0.35% | $570,991 | 100.3K |
| 6 | ROIVRoivant Sciences Ltd. | SHS | 0.03% | $44,718 | 3.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $56M | 4 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $59M | 3 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $68M | 4 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $130M | 5 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $87M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $226M | 6 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $163M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $143M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $115M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 5 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $106M | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $135M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $94M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $95M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 5 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $741M | 5 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.